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Abstract
Background: MicroRNA (miR) miR-34a, -34b/c, -124-1 and -203 are tumor suppressor miRs implicated in
carcinogenesis.
Methods: We studied DNA methylation of these miRs in Philadelphia-negative (Ph-ve) myeloproliferative
neoplasms (MPNs). Methylation-specific PCR (MSP), verified by direct sequencing of the methylated MSP products,
was performed in cell lines, normal controls and diagnostic marrow samples of patients with MPNs.
Results: Methylation of these miRs was absent in the normal controls. miR-34b/c were homozygously methylated
in HEL cells but heterozygously in MEG-01. In HEL cells, homozygous miR-34b/c methylation was associated with
miR silencing, and 5-aza-2’-deoxycytidine treatment led to re-expression of both miR-34b and miR-34c, consistent
with that both miRs are under the regulation of the same promoter CpG island. miR-34a was heterozygously
methylated in MEG-01 and K-562. miR-203 was completely unmethylated in K-562 and SET-2 but no MSP
amplification was found in both HEL and MEG-01, suggestive of miR deletion. In primary samples, four each had
miR-34b/c and -203 methylation, in which two had concomitant methylation of miR-34b/c and -203. miR-34a was
methylated in one patient and none had methylation of miR-124-1. Seven patients (15.6%) had methylation of at
least one of the four miRs. miR methylation did not correlate with clinical parameters, disease complications or
JAK2 V617F mutation.
Conclusion: This is the first report of miR hypermethylation in MPNs. miR-203 hypermethylation is not specific to
Ph+ve leukemias but also present in Ph-ve MPNs. miR-34b/c methylation was associated with reversible miR
silencing. There was no correlation of miR methylation with clinical demographic data or outcome.
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Background
Philadelphia-negative (Ph-ve) myeloproliferative neoplasm
(MPN) is a stem cell disease with proliferation of myeloid
lineage, leading to the development of distinct clinical
entities including polycythemia vera (PV), essential throm-
bocythemia (ET) and primary myelofibrosis (PMF) [1-3].
JAK2 V617F mutation, resulting in constitutive activation
of JAK-STAT signaling, occurs in about half of the
patients with ET and PMF but in more than 90% of
patients with PV [1].
Gene methylation is an alternative mechanism of gene
inactivation, and various tumor suppressor genes regu-
lating the cell cycle, apoptosis and cell signaling have
been shown to be hypermethylated in hematological
malignancies [4].
MicroRNA (miR) is a single-stranded, non-coding RNA
molecule of 22-25 nucleotides, which leads to downregu-
lation of target protein expression [5]. miRs are involved
in carcinogenesis [6]. miRs can be either oncogenic
(oncomir) when tumor suppressor genes (TSG) are tar-
geted, or tumor suppressive (tumor suppressor miRs)
when oncogenes are targeted [7].
Recently, miR-34a, miR-34b/c, miR-124-1 and miR-203
hypermethylation have been implicated in carcinogenesis.
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Hypermethylation of miR-34a, a transcriptional target of
p53, has been demonstrated in solid and hematopoietic
cancers [8,9], whereas restoration of which will inhibit
CDK6 translation by complementary binding to the 3’
untranslated region (3’ UTR) of the CDK6 mRNA and
induce apoptosis, thereby showing the tumor suppressor
role of miR-34a [8]. Epigenetic inactivation of miR-34b,
another p53 downstream target of the miR-34 family, has
also been implicated in acute myeloid leukemia (AML),
and the re-expression of miR-34b led to suppression of
CREB expression and inhibition of cell proliferation [10].
Promoter methylation of miR-124-1, the first tumor sup-
pressor miR found to be regulated by DNA methylation,
has been shown to confer poor prognosis of acute lym-
phoblastic leukemia (ALL) [11]. Moreover, hypermethyla-
tion of miR-203 has been reported in chronic myeloid
leukemia (CML), conferring a proliferative advantage to
the tumor cells by inhibiting the oncogenic BCR-ABL
fusion protein [12]. In Ph-ve MPN, little is known about
the epigenetic alteration of miR methylation. In this
report, we studied the methylation status of miR-34a,
miR-34b/c, miR-124-1 and miR-203 in PV, ET and PMF.
Methods
Patient samples
DNA was extracted from primary marrow samples at diag-
nosis of 45 patients with MPN [ET, N = 34 (75.5%); PV,
N = 8 (17.8%) and PMF, N = 3 (6.7%)]. There were
24 (53.3%) male and 21 (46.7%) female patients with a
median age of 67.5 years (range: 28 - 89 years), a median
presenting platelet count of 848 × 109/L (range: 196 -
2275 × 109/L), a median presenting hemoglobin level (Hb)
13.3 g/dL (range: 9-22 g/dL), and a median presenting leu-
kocyte count of 14.4 × 109/L (range: 7-28 × 109/L). Apart
from five (11.1%) patients in whom the presenting sympto-
matology at presentation were not available for review,
25 (62.5%) were asymptomatic at diagnosis, four (10%)
with bleeding, four (10%) with erythromelalgia, two (5%)
with minor stroke, three (7.5%) with abdominal pain, and
one each (2.5%) with blurred vision and weight loss. Of 39
patients with adequate follow-up information, five (12.8%)
had myeloid transformations (MDS or AML) at the time of
study. Of 40 patients with data on thrombosis, nine (22.5%)
had thrombotic events. Apart from 5 patients with
unknown JAK2 mutation status, 26 (65%) had JAK2 V617F
mutation. (Table 1) The study has been approved by
Institutional Review Board of Queen Mary Hospital with
written informed consent.
Cell lines and culture
MEG-01 and K-562 cells were kindly provided by Dr Mo
Yang, Department of Paediatrics, Queen Mary Hospital,
The University of Hong Kong, Hong Kong. HEL cells
were obtained from Dr Dong-Er Zhang, Department of
Pathology and Molecular Biology, Moores Cancer Center,
University of California San Diego, USA. SET-2 cells were
purchased from Deutsche Sammlung von Mikroorganis-
men und Zellkulturen GmbH (DMSZ) (Braunschweig,
Germany). SET-2 was derived from ET at megakaryoblas-
tic leukemic transformation. HEL was derived from AML
M6. Both SET-2 and HEL cells carry JAK2 V617F muta-
tion. MEG-01 and K-562 were derived from blastic trans-
formation of patients with CML. Cell cultures were
maintained in RPMI media 1640 (Invitrogen, Carlsbad,
CA), supplemented with 10% (20% for SET-2) fetal bovine
serum (Invitrogen, Carlsbad, CA), 50 U/ml penicillin, and
50 μg/ml streptomycin (Invitrogen, Carlsbad, CA) in a
humidified atmosphere of 5% CO2 at 37°C.
Methylation-specific polymerase chain reaction (MSP)
DNA was extracted from bone marrow samples at diagno-
sis and from cell lines by standard method. MSP for aber-
rant gene promoter methylation was performed as
previously described [13,14]. Treatment of DNA with
bisulfite for conversion of unmethylated cytosine to uracil
(but unaffecting methylated cytosine) was performed with
a commercially available kit (EpiTect Bisulfite Kit, Qiagen,
Germany). Primers used for the methylated MSP (M-
MSP) and unmethylated MSP (U-MSP) were shown in
Table 2. DNA from normal bone marrow donors was
used as negative control, while enzymatically methylated
control DNA (CpGenome Universal Methylated DNA,
Chemicon) was used as positive control in all the experi-
ments. MSP was performed in a thermal cycler (9700,
Applied Biosystems, Foster City, CA) with the following
cycling conditions: 95°C for 5 minutes, specific cycles of
95°C for 30 seconds, specific annealing temperature for 30
seconds (Table 2), 72°C for 30 seconds, and a final exten-
sion of 10 minutes at 72°C. The MSP mixture contained
50 ng of bisulfite-treated DNA, 0.2 mM dNTPs, MgCl2
(Table 2), 10 pmol of each primer, 1 × PCR buffer, and 2.5
units of AmpliTaq Gold DNA Polymerase (Applied Bios-
ciences, Foster City, CA) in a final volume of 25 μl. Ten
microliters of PCR products were loaded onto 6% non-
denaturing polyacrylamide gels, electrophoresed, and
visualized under ultraviolet light after staining with ethi-
dium bromide.
5-aza-2’-deoxycytidine (5-AzadC) treatment
HEL cells were homozygously methylated for miR-34b/c.
Cells were seeded in six-well plates at a density of 1 × 106
cells/ml, and cultured with 1.5 μM of 5-AzadC for 7 days.
Cells on day 0 and day 7 of treatment were harvested.
RNA isolation and stem-loop reverse transcription-
polymerase chain reaction (RT-PCR)
Total RNA was isolated using mirVana™ miRNA Isolation
Kit (Ambion, Austin, TX), according to the manufacturer’s
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Table 1 Patient demographic data and status of microRNA methylation
sex age Diagnosis Symptoms at diagnosis myeloid transformation JAK2 V617F mutation miR-34b/c miR-34a miR-203 miR-124-1
F 78 ET Epigastric pain No yes U U M U
F 81 ET Epigastric pain No yes U U U U
M 32 ET erythromelalgia No yes U U U U
M 81 ET N/A No yes U U U U
M 59 ET N/A N/A (No record) yes M U U U
M 76 ET Nil No yes U M U U
M 53 ET Nil MDS yes U U U U
F 89 ET Nil N/A (No record) yes U U U U
F 43 ET Nil N/A (No record) yes M U M U
F 82 ET Nil No yes U U U U
M 78 ET Nil No yes U U U U
F 79 ET Nil No yes U U U U
M 84 ET Nil AML yes U U U U
F 74 ET Nil No yes M U M U
F 56 ET Nil No yes U U U U
M 60 ET Nil No N/A U U U U
M 68 ET Nil AML yes U U U U
M 39 ET Nil No yes U U U U
F 79 ET Weight loss No yes U U U U
F 60 ET erythromelalgia No no U U U U
M 63 ET Minor stroke (LUL numbness) No no U U U U
M 47 ET erythromelalgia No no U U U U
F 62 ET erythromelalgia, Headache No no U U U U
F 83 ET N/A N/A (No record) no U U M U
F 32 ET Nil N/A (No record) no U U U U
F 42 ET Nil No no M U U U
M 85 ET Nil No no U U U U
M 71 ET Nil No no U U U U
F 28 ET Nil No no U U U U
F 87 ET Nil No no U U U U
M 48 ET Nil No no U U U U
M 48 ET Nil No no U U U U
M 41 ET epistaxis No N/A U U U U
M 82 ET N/A No N/A U U U U
F 41 PMF Easy bruising N/A (No record) yes U U U U
M 67 PMF Nil No yes U U U U
F 82 PMF Nil No yes U U U U
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Table 1 Patient demographic data and status of microRNA methylation (Continued)
F 42 PV Minor stroke (RUL paraesthesia) No yes U U U U
M 48 PV Gum bleeding No yes U U U U
F 75 PV Nil AML yes U U U U
M 78 PV Nil No yes U U U U
M 57 PV Visual blurring (BRAO) No yes U U U U
M 44 PV abdominal pain (splenic infarction) No no U U U U
M 71 PV Gum bleeding MDS N/A U U U U
F 77 PV N/A No N/A U U U U
Abbreviations: ET: essential thrombocythemia; PV: polycythemia vera; PMF: primary myelofibrosis; CVA: cerebrovascular acccident; BRAO: branch retinal vein occlusion; LUL: left upper limb; RUL: right upper limb;
AML: acute myeloid leukemia; MDS: myelodysplastic syndrome; N/A: not available; U: unmethylated; M: methylated
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instructions. RT was performed using Taqman® Micro-
RNA RT Kit and Taqman® MicroRNA Assay Kit (Applied
Biosciences, Foster City, CA), according to the manufac-
turer’s instructions. Total RNA was reverse transcribed in
1 mM dNTPs, 50 U MultiScribe™ Reverse Transcriptase,
1X RT Buffer, 3.8 U RNase Inhibitor, and 1X stem-loop
RT primer at the following thermal cycling condition: 16°C
for 30 minutes, 42°C for 30 minutes, and 85°C for 5 min-
utes. Quantitative real-time PCR was performed using 1.33
μl of 1:15 diluted RT product in 1X Taqman® Universal
PCR Master Mix, and 1X Taqman® Assay at 95°C for
10 minutes, followed by 40 cycles of 95°C for 15 seconds
and 60°C for 1 minute. RNU48 was used as reference for
data analysis using the 2-ΔΔCt method [15]. Conventional
RT-PCR for primary miR-34a was performed as previously
described [9].
Statistical analysis
Correlation between combined miR methylation status
(i.e. those with methylation of any of these four miRs)
with categorical variables (gender, MPN subtype, occur-
rence of myeloid transformation, development of throm-
bosis [either at diagnosis or after diagnosis of MPN] and
presence of JAK2 V617F mutation) and continuous vari-
ables (age, presenting Hb, leukocyte and platelet counts)
was computed by the Chi-square test (or Fisher Exact
test) and Student’s T-test. All p-values were two-sided.
Results
MSP
Controls
Direct sequencing of the M-MSP products from the
methylated positive control confirmed the MSP specifi-
city and complete bisulfite conversion, which methylated
cytosine remained as cytosine upon sequencing (under-
lined) while unmethylated cytosine appeared as thymi-
dine (Figure 1A). The positive and negative controls
showed expected MSP results with normal DNA showing
positive U-MSP but negative M-MSP amplification; and
conversely, methylated control DNA showing negative
U-MSP but positive M-MSP amplification. None of the 8
normal control marrows showed aberrant methylation of
miR-34a, -34b/c, -124-1 or -203 (Figure 1B).
Cell lines
MSP analysis of the four cell lines showed that miR-34a
was hemizygously methylated in MEG-01 and K-562
and completely unmethylated in HEL and SET-2. miR-
34b/c was completely methylated in HEL, hemizygously
methylated in MEG-01 and completely unmethylated in
K-562 and SET-2. miR-124-1 was completely unmethy-
lated in all the four cell lines. miR-203 was completely
unmethylated in K-562 and SET-2. However, there was
neither U- or M-MSP signals of miR-203 in both HEL
and MEG-01, suggesting a possibility of homozygous
deletion (Table 3; Figure 1C).
Primary samples
In the 45 primary bone marrow samples, miR-34a was
methylated in one (2.2%), miR-34b/c in four (8.9%), miR-
203 in four (8.9%) of patients but none had methylation of
miR-124-1 (Figure 2; Table 1). Moreover, two (4.4%) had
concomitant methylation of miR-34b/c and -203 but none
had concomitant methylation of miR-34a and -34b/c.
Direct sequencing of the methylated MSP products con-
firmed methylation of miRs in the primary samples (Figure
2). With regards to the MPN subtype, miR-34a methyla-
tion occurred in a patient with ET (2.9%), and miR-203 in
four patients (11.8%) with ET. On the other hand, miR-
34b/c methylation occurred in three patients (8.8%) with
ET and one patient (12.5%) with PV. Overall, seven
patients (15.6%) had methylation of at least one of the
three miRs. miR methylation was not associated with age
(p = 0.651), gender (p = 0.225), MPN subtype (p = 0.484),
presenting Hb (p = 0.874), presenting leukocyte count
(p = 0.969), presenting platelet count (p = 0.328), myeloid
Table 2 MSP primer sequences and reaction conditions
Gene Forward primer (5’ - 3’) Reverse primer (5’ - 3’) MgCl2/Tm/Cycles Reference
miR-34a
M-MSP GGGGATGAGGATTAGGATTTC ACAAAACGCATAAAAACGACG 1.5 mM/58°C/35 [9]
U-MSP GGGGATGAGGATTAGGATTTT CAAACAAAACACATAAAAACAACA 1.5 mM/58°C/35
miR-34b/c
M-MSP ATTCGTTTCGTTTCGCGTTCGTTTC CGACTACAACTCCCGAACGATCCG 2.0 mM/58°C/35 [34,35]
U-MSP TTTTTATTTGTTTTGTTTTGTGTTTGTTTTG CAACTACAACTCCCAAACAATCC 1.25 mM/56°C/38
miR-124-1
M-MSP AAAGAGTTTTTGGAAGACGTC AATAAAAAACGACGCGTATA 1.5 mM/55°C/35 [36]
U-MSP AATAAAGAGTTTTTGGAAGATGTT AAAAAAATAAAAAACAACACATATAC 2.0 mM/55°C/35
miR-203
M-MSP GAGTATTTTCGGTTTAGACGAGAC CCTTTTATACGACGCAACCG 1.5 mM/58°C/35 [37]
U-MSP TTTGAGTATTTTTGGTTTAGATGAGAT AACACCTTTTATACAACACAACCA 1.5 mM/58°C/35
Abbreviations: Tm, annealing temperature; M-MSP, MSP for the methylated allele; U-MSP, MSP for the unmethylated allele
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Figure 1 Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203. A) Sequence analysis of the M-MSP product from bisulfite-treated
positive control DNA showed that the cytosine [C] residues of CpG dinucleotides were methylated and remained unchanged, whereas all the
other C residues were unmethylated and were converted to thymidine [T], confirming complete bisulfite conversion and MSP specificity. B) M-/
U-MSP analysis showed that all the eight normal controls [N1-N8] were unmethylated. C) In the cell lines, MEG-01 and K-562 were hemizygously
methylated for miR-34a; HEL was completely methylated, MEG-01 was hemizygously methylated for miR-34b/c; all the four cell lines were
unmethylated for miR-124-1; K-562 and SET-2 were completely unmethylated for miR-203.
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transformation (p = 0.99), thrombotic events (p = 0.311)
or JAK2 V617F mutation (p = 0.99).
5-AzadC treatment of HEL cells
Untreated HEL cells were homozygously methylated for
miR-34b/c (Chr. 11q23). After 5-AzadC hypomethyla-
tion treatment, miR-34b/c U-MSP signal emerged,
together with about 3-fold increase in expression of
both mature miR-34b and miR-34c on day 7 as analyzed
by stem-loop RT-PCR (Figure 3). On the other hand,
miR-34a was unmethylated in HEL. By conventional
RT-PCR of the primary transcript of miR-34a, pri-miR-
34a was not constitutively expressed, and treatment
with 5-AzadC did not lead to expression of primary
miR-34a (Additional file 1).
Discussion
Little information is available about the role of miRs in
MPNs. Based on a literature search on the PubMed using
keywords of “microRNA, methylation and myeloprolifera-
tive”, no publication could be found. Therefore, this is likely
the first report on methylation of miRs in MPN. In this
study, we examined the methylation of miR-34a, -34b/c,
-124-1 and -203 for a range of MPNs. In an attempt to
identify miRs specifically involved in erythropoiesis, miR
expression from in vitro expansion of erythroid cells
derived from peripheral blood mononuclear cells were
compared with controls, which showed miR-451 upregula-
tion was specific to erythropoiesis [16]. On the other hand,
during in vitro differentiation of megakaryocytes derived
from CD34+ hematopoietic progenitors, downregulation of
miR-10a, -10b, -17, -20, -106 and -126 was observed [17].
Moreover, when comparing the miR expression profiling of
megakaryoblastic cell line with in vitro differentiated mega-
karyocytes, upregulation of miR-99a, -101, -126, and -135
was also found [17]. Therefore, the upregulation and down-
regulation of these specific miRs were associated with
megakaryocytic and erythropoietic differentiation.
Despite that multiple TSGs were shown to be silenced
by hypermethylation in AML [4,14,18-22], methylation of
tumor suppressor genes was less frequently reported in
MPN. Only recently, there were a few reports of methyla-
tion of the negative regulators of the JAK-STAT signaling
pathway, SOCS1, SOCS2 and SOCS3, in Ph-ve MPN
regardless of the JAK2 V617F mutation status [23-26].
Furthermore, based on previous work by us and others,
CDK6 has been shown to be the target of multiple miRs
including miR-34a, -34b/c and -124-1 [27,28]. Moreover,
CREB is the target of miR-34b and -203 [10,29]. Finally,
ABL is an additional target of miR-203 [12]. Consequently,
epigenetic silencing of tumor suppressor miR-34a, miR-
34b/c, miR-124-1 and miR-203 will confer proliferative
advantage to the tumor cells [27-29]. In contrast to a pre-
vious report which showed miR-203 was methylated in Ph
+ve but not Ph-ve MPN or leukemia, using MSP primers
in the similar region [12], we demonstrated that miR-203
was hypermethylated in primary MPN samples, which was
further verified by direct sequencing of the methylated
MSP products. Therefore, it would appear that miR-203
methylation is involved in a wider spectrum of MPNs or
leukemias, regardless of their Ph chromosome status.
Finally, while two patients had concomitant methylation
of miR-203 and -34b/c, none had concomitant methylation
of miR-34a and -34b/c, both transcriptional targets of p53,
and hence avoiding duplication of tumor suppressor gene
inactivation of the same pathway.
In HEL and MEG-01 cells, both U- and M-MSP signals
of miR-203 were absent, which might be due to the follow-
ing possibilities: (1) sample DNA degradation, (2) inap-
propriate PCR condition, or (3) homozygous deletion of
the region. Since simultaneous U-MSP analysis of the
same DNA sample for miR-34a, miR-34b/c, and miR-124-
1 promoter successfully generated the U-MSP signals,
hence the absence of MSP signals for miR-203 in HEL and
MEG-01 cells could not be explained by a poor DNA
quality. Moreover, as miR-203 U-MSP was successful in
all the other samples including cell lines, normal controls,
patient samples and methylated positive control, inap-
propriate MSP conditions appears unlikely. Therefore, the
absence of both M- and U-MSP signals in HEL and MEG-
01 cells might be caused by deletions of the region. How-
ever, karyotypic data of HEL and MEG-01 cells did not
reveal homozygous deletion of 14q32, and hence whether
absence of MSP amplification of miR-203 might be due to
microdeletion of this region requires further study [30].
Furthermore, hypomethylation treatment of the HEL cells,
which was homozygously methylated for the miR-34b/c, a
microRNA cluster localized to 11q23, showed significant
re-expression of mature miR-34b and miR-34c. This
Table 3 MSP of miRs in cell lines
miR-34a miR-34b/c miR-124-1 miR-203
Chromosomal location of miR 1p36 11q23 8p23 14q32
HEL UU MM UU -/-
MEG-01 UM UM UU -/-
K-562 UM UU UU UU
SET-2 UU UU UU UU
UU: completely unmethylated; UM: hemizygously methylated; MM: homozygously methylated;
-/-: absence of both U- and M-MSP signals
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Figure 2 Methylation of miR-34a, miR-34b/c, miR-124-1 and miR-203 in primary samples. For each of these miRs, M-/U-MSP and
sequencing of the M-MSP product from representative bisulfite-treated primary samples were shown. In the sequence analysis of the M-MSP
product, cytosine [C] residues of CpG dinucleotides were methylated and remained unchanged, partially methylated C residues were denoted as
[C/T], unmethylated C residues were converted into [T], whereas all the non-CpG C residues were unmethylated and were converted to
thymidine [T], confirming complete bisulfite conversion and MSP specificity.
Chim et al. Journal of Translational Medicine 2011, 9:197
http://www.translational-medicine.com/content/9/1/197
Page 8 of 10
finding is consistent with that both miR-34b and miR-34c
are under the promoter regulation of the same CpG
island. By contrast, miR-34a, another member of the miR-
34 family localized to 1p36, was not constitutively
expressed. Moreover, hypomethylating treatment did not
lead to expression of primary miR-34a, suggesting addi-
tional mechanism, possibly histone modification, in the
regulation of miR-34a expression [9]. Furthermore, in
addition to showing miR silencing in cell line, it is impor-
tant to show the correlation of miR methylation and miR
expression in the primary sample. In this connection, we
shall collect both DNA and RNA from diagnostic bone
marrow samples in the future.
In order to identify miRs that are methylated specifically
at the time of transformation to AML or MDS, and hence
implicated for pathogenesis of myeloid transformation,
ideally one should analyze the paired marrow samples at
both diagnosis and leukemic/myelodysplastic transforma-
tion. This is exemplified by our recent publication in the
study of epigenetic inactivation of miR-34b/c methylation
in myeloma, in which we showed that while miR-34b/c is
not methylated at diagnosis, it is frequently methylated at
the time of relapse or disease progression. This is as evi-
denced by the significantly more frequent methylation of
miR-34b/c of myeloma samples at relapse in patients with
both diagnostic and relapse marrow samples[31].
Finally, unlike the association of TSG with clinical
parameters, such as the association of CDKN2B and
WIF1 methylation with high presenting leukocyte count
in acute promyelocytic leukemia [32,33], methylation of
these miRs did not correlate with demographic, present-
ing blood counts, JAK2 V617F mutation or complica-
tions including thrombosis and myeloid transformations.
Conclusion
This is the first report of miR hypermethylation in
MPNs. miR-203 hypermethylation is not specific to Ph
+ve leukemias but also present in Ph-ve MPNs. miR-
34b/c methylation was associated with reversible miR
silencing. There was no correlation of miR methylation
with clinical demographic data or outcome.
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Author details
1Department of Medicine, Queen Mary Hospital, The University of Hong
Kong, Hong Kong. 2Department of Pathology, Queen Mary Hospital, The
University of Hong Kong, Hong Kong. 3Department of Human and Animal
Cell Cultures, DSMZ - German Collection of Microorganisms and Cell
Cultures, Inhoffenstr. 7B 38126 Braunschweig, Germany. 4Department of
Pathology, Queen Elizabeth Hospital, Hong Kong.
Authors’ contributions
All authors read and approved the final manuscript. CSC is responsible for
design of study, interpretation of data and writing manuscript. TSW is
responsible for provision of study material. KYW and TKF are responsible for
conduction of experiment. HGD is responsible for provision of cell lines. KFW
is responsible for provision of patients’ material.
Competing interests
The authors declare that they have no competing interests.
Received: 7 April 2011 Accepted: 14 November 2011
Published: 14 November 2011
References
1. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, Barosi G,
Verstovsek S, Birgegard G, Mesa R, et al: Proposals and rationale for
revision of the World Health Organization diagnostic criteria for
polycythemia vera, essential thrombocythemia, and primary
myelofibrosis: recommendations from an ad hoc international expert
panel. Blood 2007, 110:1092-1097.
2. Chim CS, Kwong YL, Lie AKW, Ma SK, Chan CC, Wong LG, San Kho BC,
Lee HK, Sim JPY, Chan CH, et al: Long-term Outcome of 231 Patients With
Essential Thrombocythemia: Prognostic Factors for Thrombosis,
Bleeding, Myelofibrosis, and Leukemia. Arch Intern Med 2005,
165:2651-2658.
3. Chim CS, Kwong YL, Chan PT, Raymond L: Polycythemia vera in Chinese
patients: Thirty-six years of experience. American Journal of Hematology
1997, 56:59-62.
4. Chim CS, Liang R, Kwong YL: Hypermethylation of gene promoters in
hematological neoplasia. Hematol Oncol 2002, 20:167-176.
5. Chen CZ: MicroRNAs as Oncogenes and Tumor Suppressors. N Engl J
Med 2005, 353:1768-1771.
6. Calin GA, Croce CM: MicroRNA signatures in human cancers. Nat Rev
Cancer 2006, 6:857-866.
7. Esquela-Kerscher A, Slack FJ: Oncomirs - microRNAs with a role in cancer.
Nat Rev Cancer 2006, 6:259-269.
Figure 3 Effect of 5-aza-2’-deoxycytidine (5-AzadC) treatment
on HEL cells. A) M-/U-MSP analysis of miR-34b/c promoter
methylation status showed that 5-AzadC treatment led to
progressive demethylation of miR-34b/c promoter in HEL cells. B)
Stem-loop qRT-PCR analysis of mature miR-34b and miR-34c
expression in HEL cells seven days after treatments. Error bar
represents standard deviation.
Chim et al. Journal of Translational Medicine 2011, 9:197
http://www.translational-medicine.com/content/9/1/197
Page 9 of 10
8. Lodygin D, Tarasov V, Epanchintsev A, Berking C, Knyazeva T, Korner H,
Knyazev P, Diebold J, Hermeking H: Inactivation of miR-34a by aberrant
CpG methylation in multiple types of cancer. Cell Cycle 2008, 7:2591-2600.
9. Chim CS, Wong KY, Qi Y, Loong F, Lam WL, Wong LG, Jin DY, Costello JF,
Liang R: Epigenetic inactivation of the miR-34a in hematological
malignancies. Carcinogenesis 2010, 31:745-750.
10. Pigazzi M, Manara E, Baron E, Basso G: miR-34b Targets Cyclic AMP-
Responsive Element Binding Protein in Acute Myeloid Leukemia. Cancer
Res 2009, 69:2471-2478.
11. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, Martin-Subero JI, Cordeu L,
Garate L, San Jose-Eneriz E, Abizanda G, Rodriguez-Otero P, Fortes P, et al:
Epigenetic Silencing of the Tumor Suppressor MicroRNA Hsa-miR-124a
Regulates CDK6 Expression and Confers a Poor Prognosis in Acute
Lymphoblastic Leukemia. Cancer Res 2009, 69:4443-4453.
12. Bueno MJ, Perez de Castro I, Gomez de Cedron M, Santos J, Calin GA,
Cigudosa JC, Croce CM, Fernandez-Piqueras J, Malumbres M: Genetic and
Epigenetic Silencing of MicroRNA-203 Enhances ABL1 and BCR-ABL1
Oncogene Expression. Cancer Cell 2008, 13:496-506.
13. Chim CS, Fung TK, Cheung WC, Liang R, Kwong YL: SOCS1 and SHP1
hypermethylation in multiple myeloma: implications for epigenetic
activation of the Jak/STAT pathway. Blood 2004, 103:4630-4635.
14. Chim CS, Liang R, Tam CYY, Kwong YL: Methylation of p15 and p16
Genes in Acute Promyelocytic Leukemia: Potential Diagnostic and
Prognostic Significance. J Clin Oncol 2001, 19:2033-2040.
15. Livak KJ, Schmittgen TD: Analysis of Relative Gene Expression Data Using
Real-Time Quantitative PCR and the 2-[Delta][Delta]CT Method. Methods
2001, 25:402-408.
16. Bruchova H, Yoon D, Agarwal AM, Mendell J, Prchal JT: Regulated
expression of microRNAs in normal and polycythemia vera
erythropoiesis. Experimental Hematology 2007, 35:1657-1667.
17. Garzon R, Pichiorri F, Palumbo T, Iuliano R, Cimmino A, Aqeilan R, Volinia S,
Bhatt D, Alder H, Marcucci G, et al: MicroRNA fingerprints during human
megakaryocytopoiesis. Proceedings of the National Academy of Sciences of
the United States of America 2006, 103:5078-5083.
18. Chim CS, Tam CYY, Liang R, Kwong YL: Methylation of p15 and p16 genes
in adult acute leukemia. Cancer 2001, 91:2222-2229.
19. Chim CS, Wong ASY, Kwong YL: Epigenetic inactivation of the CIP/KIP
cell-cycle control pathway in acute leukemias. American Journal of
Hematology 2005, 80:282-287.
20. Chim CS, Wong SY, Pang A, Chu P, Lau JS, Wong KF, Kwong YL: Aberrant
promoter methylation of the retinoic acid receptor alpha gene in acute
promyelocytic leukemia. Leukemia 2005, 19:2241-2246.
21. Chim CS, Wong ASY, Kwong YL: Epigenetic dysregulation of the Jak/STAT
pathway by frequent aberrant methylation of SHP1 but not SOCS1 in
acute leukaemias. Annals of Hematology 2004, 83:527-532.
22. Chim CS, Wong SY, Kwong YL: Aberrant gene promoter methylation in
acute promyelocytic leukaemia: profile and prognostic significance. Br J
Haematol 2003, 122:571-578.
23. Capello D, Deambrogi C, Rossi D, Lischetti T, Piranda D, Cerri M, Spina V,
Rasi S, Gaidano G, Lunghi M: Epigenetic inactivation of suppressors of
cytokine signalling in Philadelphia-negative chronic myeloproliferative
disorders. British Journal of Haematology 2008, 141:504-511.
24. Quentmeier H, Geffers R, Jost E, MacLeod RAF, Nagel S, Rohrs S, Romani J,
Scherr M, Zaborski M, Drexler HG: SOCS2: inhibitor of JAK2V617F-
mediated signal transduction. Leukemia 2008, 22:2169-2175.
25. Fourouclas N, Li J, Gilby DC, Campbell PJ, Beer PA, Boyd EM, Goodeve AC,
Bareford D, Harrison CN, Reilly JT, et al: Methylation of the suppressor of
cytokine signaling 3 gene (SOCS3) in myeloproliferative disorders.
Haematologica 2008, 93:1635-1644.
26. Chim CS, Fung TK, Liang R: Methylation of cyclin-dependent kinase
inhibitors, XAF1, JUNB, CDH13 and soluble Wnt inhibitors in essential
thrombocythaemia. Journal of Clinical Pathology 2010, 63:518-521.
27. Wong KY, So CC, Loong F, Chung LP, Lam WWL, Liang R, Li GKH, Jin D-Y,
Chim CS: Epigenetic Inactivation of the miR-124-1 in Haematological
Malignancies. PLoS One 2011, 6:e19027.
28. Wong KY, Yu L, Chim CS: DNA methylation of tumor suppressor miRNA
genes: a lesson from the miR-34 family. Epigenomics 2011, 3:83-92.
29. Wong KY, Liang R, So CC, Jin DY, Costello JF, Chim CS: Epigenetic silencing
of MIR203 in multiple myeloma. British Journal of Haematology 2011,
154:569-578.
30. Drexler HG: Guide to Leukemia-Lymphoma Cell Lines. 2 edition.
Braunschweig; 2010.
31. Wong KY, Yim RLH, So CC, Jin D-Y, Liang R, Chim CS: Epigenetic
inactivation of the MIR34B/C in multiple myeloma. Blood 2011,
118:5901-5904.
32. Chim CS, Chan WWL, Pang A, Kwong YL: Preferential methylation of Wnt
inhibitory factor-1 in acute promyelocytic leukemia: an independent
poor prognostic factor. Leukemia 2006, 20:907-909.
33. Chim CS, Kwong YL: Adverse prognostic impact of CDKN2B hyper-
methylation in acute promyelocytic leukemia. Leukemia & Lymphoma
2006, 47:815-825.
34. Lujambio A, Calin GA, Villanueva A, Ropero S, Sanchez-Cespedes M,
Blanco D, Montuenga LM, Rossi S, Nicoloso MS, Faller WJ, et al: A
microRNA DNA methylation signature for human cancer metastasis.
PNAS 2008, 0803055105.
35. Toyota M, Suzuki H, Sasaki Y, Maruyama R, Imai K, Shinomura Y, Tokino T:
Epigenetic Silencing of MicroRNA-34b/c and B-Cell Translocation Gene 4
Is Associated with CpG Island Methylation in Colorectal Cancer. Cancer
Res 2008, 68:4123-4132.
36. Lujambio A, Ropero S, Ballestar E, Fraga MF, Cerrato C, Setien F, Casado S,
Suarez-Gauthier A, Sanchez-Cespedes M, Gitt A, et al: Genetic Unmasking
of an Epigenetically Silenced microRNA in Human Cancer Cells. Cancer
Res 2007, 67:1424-1429.
37. Chim CS, Wong KY, Leung CY, Chung LP, Hui PK, Chan SY, Yu L: Epigenetic
inactivation of the hsa-miR-203 in haematological malignancies. Journal
of Cellular and Molecular Medicine 2011, 15:2760-2767.
doi:10.1186/1479-5876-9-197
Cite this article as: Chim et al.: Methylation of miR-34a, miR-34b/c, miR-
124-1 and miR-203 in Ph-negative myeloproliferative neoplasms.
Journal of Translational Medicine 2011 9:197.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Chim et al. Journal of Translational Medicine 2011, 9:197
http://www.translational-medicine.com/content/9/1/197
Page 10 of 10
